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“Collisiontumor”isanuncommonphenomenoncharacterizedbycoexistenceoftwocompletelydistinctandindependenttumors
at the same site. Collision tumors have been reported in diﬀerent sites in the body; however, these are particularly uncommon in
the pelvic cavity. A 70-year-old man, with prior history of urothelial and prostate cancer, presented with a large pelvic mass
detected on imaging studies. Pathological examination revealed a large liposarcoma with prostatic carcinoma embedded in it.
Immunohistochemistry and ﬂorescence in situ hybridization studies were performed to reach to a conclusive diagnosis. To the
best of our knowledge, this is the second case reported till date. We present the challenges encountered in the diagnosis of this case
a n dr e v i e wo fp e l v i cc o l l i s i o nt u m o r s .
1.Introduction
“Collision tumor” is a well-documented but uncommon
phenomenon characterized by coexistence of two completely
distinctandindependenttumorsatthesamesite[1–11].The
two morphologically separate tumors, which are genetically
diﬀerent,aresharplydemarcatedfromeachother.Thisentity
is distinct from neoplasms demonstrating heterologous
elements, as a result of divergent diﬀerentiation [1, 4].
The previously documented cases of collision tumor are
predominantly synchronous epithelial tumors with diﬀerent
lineages such as melanoma occurring in a basal cell carci-
noma [10] or gastric adenocarcinoma within a gastrointesti-
nal stromal tumor [11], tumor to tumor metastasis [1, 2, 4,
12,13],tumorscoexistingaspartofasystemicprocess(small
cell lymphoma/chronic lymphocytic leukemia with pelvic
myelolipoma and renal cell carcinoma with intravascular
lymphomatosis) [5, 6], and two coexistent metastatic tumors
in a single lymph node [14–21]. The last category is rare and
has also been referred to as “collision metastasis” [14, 16].
The various collision tumors have been documented in dif-
ferent regions of the body including head and neck, thorax,
abdomen, and pelvic cavity. The incidence of carcinoma
metastasizingtomesenchymaltumor,especiallyinthepelvis,
is extremely rare [3, 7, 9, 12, 22]. We present a case of a
patient with both urothelial and prostate cancers where in
the prostatic carcinoma metastasized to a retroperitoneal
pleomorphic liposarcoma. The lineages of both tumors were
conﬁrmed by immunohistochemistry and ﬂorescence in situ
hybridization (FISH).2 Pathology Research International
2. ClinicalHistory
The patient was a 70-year-old man with a surgical history
signiﬁcant for high-grade urothelial carcinoma of urinary
bladder. In 2003 he presented with painless hematuria and
was found to have a tumor conﬁned entirely inside a
large urinary bladder diverticulum. Cystoscopy conﬁrmed
no tumor in the bladder cavity, and a pelvic CT did not
demonstrate any evidence of extravesical tumor spread or
metastatic disease. Microscopic examination of the prior
bladder tumor demonstrated mixture of highly atypical
malignant epithelioid and spindle cells (Figure 1), which
demonstrated diﬀuse immunoexpression of pancytokeratin
and cytokeratin 20. The tumor cells were negative for
vimentin and CD68. The features were diagnostic of high-
grade sarcomatoid urothelial carcinoma. He underwent
partial cystectomy followed by adjuvant chemotherapy and
intravesical BCG. In 2006, he had radical retropubic prosta-
tectomy and radiotherapy for a prostate adenocarcinoma,
Gleason’s score 4+4 = 8( Figure 2). Extracapsular extension,
seminal vesicle, and perineural and angiolymphatic invasion
were found on pathological examination. There were no
palpable lymph nodes; computed tomography did not show
any evidence of lymph node metastasis, and there was no
recurrence of urothelial carcinoma.
Forty-ﬁve months later, a steady rise in serum prostate-
speciﬁc antigen (PSA) from 1.9ng/mL to 8.9ng/mL was
noted over the last 4 months. A surveillance cystoscopy
showed evidence of extrinsic bladder compression which
on digital rectal examination was felt to be a ﬁrm mass.
Computed tomography with contrast of the pelvis and
abdomen showed a large, 18 × 12.7cm heterogeneous solid-
cystic mass with irregular internal enhancement. The mass,
extended from the pelvis up to the transverse segment of the
duodenum, involved the dome of the bladder, left pelvic side
wall, left ureterovesical junction, and rectosigmoid colon.
There was evidence of left-sided obstructive hydroureter and
hydronephrosis due to the tumor. No evidence of metastasis
was seen in thorax and upper abdomen.
The patient underwent resection of the tumor with en
bloc sigmoid colectomy and ureteroneocystostomy. Intra-
operatively the large mass was visualized which appeared to
be arising from pelvis with deﬁnite invasion into the sigmoid
colon, involving lower portion of left ureter and portion of
the dome of bladder. A small irregular lesion was noted in
the lower retrovesicle region which was found to be well-
diﬀerentiated prostatic adenocarcinoma on intraoperative
frozen section. The mass was entirely resected and sent for
pathological examination.
3.Pathologic Findings
3.1. Gross Findings. The resected specimen was a large, well
circumscribed, nonencapsulated, and yellow-pink multi-
nodular 18.5 × 16.0 × 11.5cm mass with an attached
segment 32.5cm of large intestine (Figure 3(a)). The cut sur-
faces of the mass were ﬁrm with multiloculated cysts, focally
hemorrhagic, and variegated tan-brown to red. The cystic
Figure 1: Sarcomatoid urothelial carcinoma. Tumor comprised of
sheets of epithelioid and plump spindle cells which are highly pleo-
morphic with nuclear hyperchromasia. There is prominent stromal
inﬂammatory response to the invading tumor with destruction
of the bladder wall. (Hematoxylin & eosin, original magniﬁcation
×100).
Figure 2: Prostatic adenocarcinoma: The large nodules of tumor
cells, invading the stroma, are arranged mainly as sheets of
cells and fused acini. Prominent perineural invasion is identiﬁed.
(Hematoxylin & eosin, original magniﬁcation ×100).
structures were smooth-walled, ﬁlled with serosanguinous
ﬂuid, and some had ragged and nodular tan-yellow lining.
3.2. Microscopic Findings. The mass was extensively sam-
pled, and subsequent histologic examination demonstrated
a malignant mesenchymal tumor with variably cellular
stroma. The cellular areas were comprised of large cells
with moderate to abundant clear to eosinophilic cytoplasm,
enlarged, highly pleomorphic, and vesicular nuclei with
distinct nucleolus, admixed with scattered pleomorphic
and bizarre multinucleated giant tumor cells (Figure 3(b)).
Scattered lipoblasts were noted in the cellular areas with
prominent plexiform vasculature (Figures 3(c) and 3(d)).
The stroma in the hypocellular areas was sclerotic to focally
myxoid with few scattered spindle cells. Also seen dispersed
in the hypocellular areas were collection of glandular tumor,
morphologically similar to the prostate carcinoma, lined
by cuboidal to columnar cells with eosinophilic to clear
cytoplasm and enlarged vesicular nuclei with prominent
nucleoli (Figures 3(e), 3(f)). Tumor was also noted in the
retrovesical tissue.
Immunohistochemical analysis revealed immunoexpres-
sion of cytokeratin AE1/AE3 (Monoclonal Mouse, DAKO,
1:100) (Figure 4(a)), CAM5.2 (Monoclonal Mouse, BD,
1:10), focal and weak P501S (Monoclonal Mouse, DAKO,Pathology Research International 3
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Figure 3: Image Plate I. (a) Gross image of the pelvic mass resection. The mass was large, well circumscribed, nonencapsulated and yellow-
pink with an attached segment of large intestine. (b) Cellular area of the tumor, comprised of large cells with enlarged, highly pleomorphic,
and vesicular nuclei with distinct nucleoli and abundant, clear to eosinophilic cytoplasm, with scattered bizarre multinucleated tumor giant
cells. The stroma appears hyalinized with delicate branching capillary network. (Hematoxylin & eosin, original magniﬁcation ×200.) (c)
Scattered lipoblasts in a variably cellular background. (Hematoxylin & eosin, original magniﬁcation ×400.) (d) Highly cellular area of tumor
showing plexiform network of delicate capillaries, admixed tumor cells, and rare lipoblast. (Hematoxylin & eosin, original magniﬁcation
×200.)(e)Glandulartumoraggregatecomprisedofvariablysizedacini(left),scatteredinahyalinizedstroma.Interfacewiththeliposarcoma
component (right) is clearly seen. (Hematoxylin & eosin, original magniﬁcation ×40.) (f) Close-up view of the prostatic carcinoma showing
well formed acini and inspissated eosinophilic luminal secretion. The acini are intricately admixed with the bizarre tumor giant cells of the
liposarcoma in a myxoid to hyalinized stroma.
1:40), and androgen receptor (AR) (Monoclonal Mouse,
DAKO, 1:100) in the glandular component. The myx-
oid and pleomorphic component was strongly positive
for vimentin (Monoclonal Mouse, Ventana, Prediluted)
(Figure 4(b)) and negative for several cytokeratin markers,
S-100 (Polyclonal rabbit, DAKO, 1:500), HMB45 (Mono-
clonal Mouse, Ventana, Prediluted), Melan-A (Monoclonal
Mouse, DAKO, 1:100), demsin (Monoclonal Mouse, Ven-
tana, Prediluted), smooth muscle actin (SMA) (Monoclonal
Mouse, Cell Marque, Prediluted), myogenin (Monoclonal
Mouse, Cell Marque, Prediluted), and CD117 (Polyclonal
rabbit, DAKO, 1:100). CD34 (Monoclonal Mouse, Ventana,
Prediluted) highlighted the prominent plexiform vasculature
(Figure 4(c)).
Florescence in situ hybridization (FISH) analysis, per-
formed using dual-color break-apart probe for CHOP
(CHOP dual-color break-apart probe, Abbott Molecular,
Des Plaines, Ill) gene (Figure 4(d)), was positive for the
translocation pattern and negative for MDM2 ampliﬁcation
(Figure 4(e)) (MDM2 clones RP11-450G15, RP11-775J10
(CHORI)/CEP12 Abbott Molecular, Des Plaines, Ill). FISH
analysisusingdual-colordouble-fusionprobesforTMPRSS2
(clone RP11-24A11 (CHORI, Oakland, Calif)) and ERG
(clone RP11-35C4 (CHORI), Oakland, Calif), demonstrated
the fusion transcript in the focus harboring prostatic adeno-
carcinoma (Figure 4(f)).
The patient is alive at 7 months followup, but has a rising
PSA from 6.1 to 8.6ng/mL. Magnetic resonance imaging
revealed a 4.2cm left pelvic cavity mass concerning for
recurrent/residual tumor.
4. Discussion
Collision tumors represent an uncommon coexistence of
tumors with distinct morphology and biology. These tumors
occurring in the pelvic cavity are rare with only 8 cases
being reported till date [2–5, 7, 9, 12, 22]( Table 1)o fw h i c h
prostate adenocarcinoma was the most frequent component
tumor. There are 4 reported cases with soft-tissue tumor
as one of the components (two leiomyosarcoma [3, 9], one
leiomyoma [22], and one liposarcoma [7]). Only 3 cases of
collision tumors with liposarcoma as one of the components
have been reported [1, 7, 24]. The collision tumor of prostate
adenocarcinoma and liposarcoma has been documented
previously as a single case report in 1978 by Juhasz and Kiss,
the current case being the second one reported till date.
In our current case, the patient had past history of
a urothelial and a prostate carcinoma, followed by the
liposarcoma (Table 2). Each epithelial tumor was treated
surgically followed by chemotherapy and radiation. There
was an approximate three-year interval between occurrence4 Pathology Research International
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Figure 4: Image Plate II. (a) Malignant prostatic acini are strongly positive for AE1/AE3. The spindle cells are negative. (Original
magniﬁcation ×100.) (b) Strong expression of vimentin in the liposarcoma component. (Original magniﬁcation ×40.) (c) CD34 highlights
the plexiform network of capillaries in the tumor. (Original magniﬁcation ×40.) (d) FISH analysis, dual-color break-apart probe for CHOP
is positive for the translocation, represented by a cell with one yellow signal (normal), one red (part of CHOP gene), and one green signal
(part of CHOP gene). (e) FISH analysis, ampliﬁcation probe for MDM2, is negative (not ampliﬁed). (f) FISH analysis, dual-color fusion
probes for TMPRSS (red) and ERG (green), is positive, represented by cells with at least one fused yellow signal (red + green).
Table 1: List of collision tumors in the pelvis.
Case no. Source Tumor 1 Tumor 2 Site
(1) Juhasz and Kiss/1978 [7] Liposarcoma Pr ACa Right seminal vesicle
(2) Erler/1978 [22] Pleomorphic carcinoma Leiomyoma True pelvis
(3) Palma et al./1983 [9] Leiomyosarcoma Pr ACa Prostate
(4) Oda et al./1984 [23] TCC bladder Colon ACa Vesicocolic ﬁstula
(5) Paveli et al./2000 [3] Rectal leiomyosarcoma Pr ACa Prostate & rectum
(6) Roh et al./2006 [2] Rectal ACa Gastric ACa Rectum
(7) Brahmania et al./2007 [4] Colon ACa Granulosa cell tumor, ovary Pelvic mass
(8) Gheith et al./2009 [5] Myelolipoma CLL/SLL Pelvic mass
PrACa: prostatic adenocarcinoma, ACa: adenocarcinoma, TCC: transitional cell carcinoma, CLL/SLL: chronic lymphocytic leukemia/small lymphocytic
lymphoma.
of the tumors, each of which was extensively studied, and
diagnosis conﬁrmed by immunohistochemistry.
It is not certain whether the liposarcoma had been
present during the initial or subsequent surgeries, since
retroperitoneal sarcomas, especially liposarcomas, can man-
ifest when they attain large size, but in this patient, each
epithelial malignancy was staged appropriately, and at diag-
nosis, no other intra-abdominal masses were detected. It is
possible that the liposarcoma was smaller and diﬀerentiated
at inception and had a growth spurt when dediﬀerentiation
occurred.
Pathological examination revealed a liposarcoma with
embedded prostatic adenocarcinoma. The diagnosis in
this case was challenging due to paucity of characteristic
lipoblasts in the high-grade sarcoma and some morphologic
similarity with the patient’s prior bladder tumor, thus
necessitating the use of ancillary tests, especially FISH, for
the liposarcoma-related gene targets.
Collision metastasis to pelvic lymph nodes is a rare event
and most frequently involved by prostate adenocarcinoma
in combination with colonic adenocarcinoma and bladder
carcinoma [15–20]. In this case, we describe that prostatic
adenocarcinoma was scattered throughout the liposarcoma,
which suggests that this best represents a tumor (prostate
adenocarcinoma) to tumor (liposarcoma) metastasis, since
no residual lymph node architecture was found.Pathology Research International 5
Table 2: Sequence of events.
Year Site Morphology IHC FISH Diagnosis Treatment
5/2003
Urinary
bladder
diverticulum
Biphasic (epithelial and
spindle cells) tumor with
high-grade cytologic
features. ALI−,P N I −,
perivesical soft-tissue
invasion
panCK+,
CK20+,
Vimentin−,
CD68−,
desmin−,
SMA−
NA
Sarcomatoid
urothelial
carcinoma
Partial cystectomy,
gemcitabine and
carboplatin (4 cycles),
intravesical BCG
10/2006 Prostate
Prostate adenocarcinoma,
Gleason’s Score 4+4=8,
ALI+, PNI+, ECE+, Seminal
vesicle involvement.
NA NA
High-grade
prostatic
adenocarcinoma
Radical prostatectomy
and radiotherapy
4/2010 Pelvic mass
Myxoid liposarcoma with
pleomorphic areas,
characteristic lipoblasts and
hyalinized stroma mingled
with well-diﬀerentiated
prostatic adenocarcinoma
Liposarcoma:
vimentin+,
S100−,S M A −,
desmin−,
HMB45−,
melan A−,
myogenin−,
CD117−
PCa: AE1/AE3+,
CAM5.2+, weak
P501S+, AR+
Liposarcoma:
CHOP+,
MDM2−
PCa:TMPRSS2−
ERG+
Dediﬀerentiated
myxoid
liposarcoma
with embedded
prostatic
adenocarcinoma
Tumor resection, en
bloc sigmoid
colectomy, and
ureteroneocystostomy
ALI: angiolymphatic invasion, AR: androgen receptor, CK: Cytokeratin, ECE: extracapsular extension, FISH: ﬂorescence in situ hybridization, IHC:
immunohistochemistry, PCa: prostatic adenocarcinoma: PNI: perineural invasion, SMA: smooth muscle actin.
Use of immunohistochemical markers helped in estab-
lishing the diagnosis of prostate adenocarcinoma based on
immunoreactivity for pancytokeratin, CAM5.2, P501S, and
AR. The sarcomatous component expressed vimentin only
and was negative for an entire battery of immunostains.
Determination of loss of heterozygosity (LOH) and poly-
merasechainreaction(PCR)canbeusedtohelpdiﬀerentiate
the components in a tumor to tumor metastasis [2, 3, 5]. We
used dual-color FISH to conﬁrm diagnosis of liposarcoma,
because of the presence of pleomorphic areas rather than
the round cell component generally associated with high-
grade myxoid liposarcoma. CHOP gene, mapped to the
long arm of chromosome (12q23) is also known as DDIT3,
encodes a member of the CCAAT/enhancer-binding protein
(C/EBP) family of transcription factors which is implicated
inadipogenesisanderythropoiesis.TheFUSgene,presenton
chromosome 16, encodes for an RNA-binding protein [25,
26]. Chromosomal translocation t(12;16)(q13;p11) leads to
fusion of 5  end of FUS gene (exons 1–5, promoter region)
and complete coding region of CHOP which causes stable
expression of the fusion protein leading to tumor formation
[26, 27]. This translocation is characteristic of myxoid
liposarcomas and seen in 95% of the cases. Three types of
fusion transcripts have been reported based on the length of
the promoter portion of FUS gene, type II being the most
common [26]. The remainder 5% of myxoid liposarcomas
have another translocation, t(12;22)(q13;q12), involving
CHOP and EWSR1 genes [26]. FISH analysis using CHOP
dual-color, break-apart probe has been reported to be the
most eﬃcient and sensitive method for diagnosis of myxoid
liposarcomas [25]. In our case, the above FISH analysis
helped in the diagnosis of dediﬀerentiated liposarcoma and
alsoruledoutthepossibilityofmetastasisfrompriorbladder
sarcomatoid carcinoma.
MDM2 gene region ampliﬁcation, characterized by the
presence of giant marker/ring chromosome 12 containing
MDM2sequences,isseeninatypicallipomatoustumor/well-
diﬀerentiatedliposarcomaanddediﬀerentiatedliposarcomas
[28]. However, the speciﬁcity of the MDM2 FISH analysis is
lower in the later case, as other pleomorphic sarcomas may
also show MDM2 ampliﬁcation [25, 26]. In the current case
FISH for MDM2 analysis was negative.
ERG, a member of the ETG family of transcription
factors, functions in conjunction with other transcription
factors in regulation of many cellular functions, prolifer-
ation, diﬀerentiation, oncogenesis, and angiogenesis [29].
TMPRSS2 is predominantly expressed in the luminal epithe-
lial cells of prostatic acini. Both the genes are located 3Mb
apart on the long arm of chromosome 21 (q22.2-22.3).
Interstitial deletion of the intervening intronic DNA in this
region is the most common mechanism for formation of
the TMPRSS2-ERG fusion transcript, which is seen in about
half of prostate cancers [29–31]. This rearrangement can be
detected either using FISH or reverse transcriptase PCR (RT-
PCR). We performed FISH analysis using dual-fusion probes
for TMPRSS2 and ERG, which demonstrated the fusion
transcript in the foci of prostatic adenocarcinoma. Although
prostate carcinomas associated with this gene rearrangement
have been reported to have a poor clinical outcome and
decreased overall survival, the data available till date is still
controversial [29].
The underlying pathobiology of collision tumors is still
uncertain; however, various hypotheses have been postulated
[1] as follows.6 Pathology Research International
(1) Occurrence of two diﬀerent tumor types in one site is
coincidental.
(2) Asinglecarcinogenicstimulusalterstheenvironment
of the region conducive for occurrence of two
diﬀerent tumors.
(3) Presence of ﬁrst tumors alters the microenvironment
favorable for development of the second tumor.
In this multiple cancer-prone individual with no history
of familial cancers, several intriguing possibilities exist. (a)
Most of the high-grade retroperitoneal sarcomas are dedif-
ferentiated liposarcomas that are frequently de novo or have
dediﬀerentiated from a preexisting low-grade liposarcoma;
the latter is most likely a temporal event [26, 32, 33].
Liposarcomas for practical purposes do not arise from pre-
existing lipomas [26]. Radiation-induced dediﬀerentiation
in liposarcomas is unlikely and has not been reported
for prostate carcinomas also. (b) All three neoplasms in
the current case must have been synchronous tumors that
became clinically manifested at diﬀerent time frames. (c)
In majority of tumor to tumor metastases, the recipient is
usually a richly vascular tumor as argued in previous reports
[34, 35]. Myxoid liposarcoma are also richly vascular and
contain distinct plexiform vasculature and, therefore, can
be considered as a recipient of the prostate adenocarcinoma
since no residual lymph node architecture was found.
In conclusion we have documented a rare case of
prostate adenocarcinoma that most likely metastasized to a
liposarcoma and grew undetected in a large dediﬀerentiated
or pleomorphic myxoid liposarcoma. It is also of interest
that this CHOP FUS-positive poorly diﬀerentiated myxoid
liposarcoma did not contain the round cell component
associated with myxoid liposarcoma, but this has been
described to occur in some myxoid liposarcomas [36].
The use of morphological features, immunohistochem-
istry, and appropriate cytogenetic tests helped in reaching
a correct diagnosis. The emphasis is on awareness amongst
clinician, and pathologists of existence of such a collision
tumor and role of extensive tumor sampling and appropriate
use of ancillary tests to arrive at a diagnosis.
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